ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Outlook 2025: Key Trends & Insights

  Dive into the key trends and challenges shaping the year ahead, from geopolitical uncertainties to cutting-edge innovation in AI, oncology, and weight-loss therapies.

• Navigating The Biopharma Finance And Accounting Tech Landscape

  During clinical trials, the intricacies of financial management intensify, necessitating advanced ERP functionalities to handle clinical accruals, compliance, and reporting.

• My Worst Nightmare In RSTM: Accidental Unblinding

  Learn how collaborative efforts from study managers, supply managers, biostatisticians, designers, and clinicians can better protect the blind in clinical trials and prevent accidental unblinding.

• 5 Tips To Put The Right Systems In Place For Successful Clinical Trials

  Before you dive into clinical trials, ask yourself: Is my company operationally ready to handle the complexity? Learn about key upgrades that can help you streamline operations and reduce risk.

• Benefits Of Electronic Labels: Investigational Medicinal Products

  When a new therapeutic drug, medical device, vaccine, or other investigational medicinal product (IMP) is developed, learn why a label must be on its packaging that provides relevant and important information.

• Is Your Clinical Supply Strategy Ready For EU CTR?

  One of the most significant changes in the new EU regulation is Annex VI, which covers changes in the labelling requirements for investigational medical products (IMPs). So, what are the implications of these changes and how will they affect outer immediate packaging? 

• Choosing RTSM? Evaluate The Team Running It, Not Just The Software

  High-performing RTSM requires more than just code. Discover why team continuity and clinical expertise are the most overlooked factors in reducing trial risk and ensuring regulatory compliance.

• Overcoming Obstacles To Deliver Critical Autologous Cell Therapy

  See how teams ensured a seamless route, including on-time customs clearance and delivery of autologous cell therapy, from the U.S. to a manufacturing site in Germany

• Running Decentralized Trials At Scale

  As the industry continues to embrace decentralized approaches, sponsors are recognizing the potential benefits of DCTs, including reduced operational costs and improved recruitment and retention of more diverse patient populations.

• Building A Flexible, Challenge Resistant, Patient-Centric Clinical Supply Chain

  Flexible solutions, like demand-led supply and direct-to-patient distribution, are helping sponsors address the growing list of challenges presented by today’s increasingly complex studies.